AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Abeona Therapeutics shares surge 19.90% after-hours after strong Q3 earnings, Zevaskyn demand, and major insurer coverage.
ByAinvest
Wednesday, Nov 12, 2025 4:30 pm ET1min read
Abeona Therapeutics (ABEO) surged 19.90% in after-hours trading following its Q3 2025 earnings report and updates on Zevaskyn, its gene therapy for RDEB. The company narrowed its net loss to $5.2M (vs. $30.3M in Q3 2024), attributed to optimized R&D spending and operational efficiency. Key drivers included strong patient demand, with identified eligible patients doubling to ~30, and broad coverage of Zevaskyn by major insurers (UnitedHealthcare, Cigna, Aetna, Anthem, and Blue Cross Blue Shield plans). These developments, alongside a $207.5M cash reserve supporting two years of operations, overshadowed a one-quarter delay in patient treatments due to a resolved sterility assay issue. The stock’s rally reflected optimism around Zevaskyn’s commercial potential and Abeona’s strategic progress in scaling treatment centers and securing market access.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet